Radiopharm Theranostics

Radiopharm Theranostics focuses on developing radiopharmaceutical products for diagnosis and treatment in areas of unmet medical need. A highly forward-looking portfolio of four distinct and clearly differentiated platform technologies. The selection of candidate pipelines is based on their potential to be first-to-market or best-in-class in their respective therapeutic applications. The entire portfolio is currently undergoing three Phase 2 and five Phase 1 trials, with a total of approximately 127 patients dosed to date.